Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Trastuzumab approved by NICE for gastric cancer

By News team

Trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, has been approved by the National Institute for Health and Clinical Excellence for the treatment of HER2-positive metastatic gastric cancer.

NICE has also updated its guidance on the use of imatinib for metastatic or unresectable gastrointestinal stromal tumours (TA86); high doses of imatinib (600–800mg/day) are not recommended for patients whose disease has progressed while taking 400mg/day.

Citation: Clinical Pharmacist URI: 11048915

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.